SUNNYVALE, Calif., Sept. 18, 2024 (GLOBE NEWSWIRE) — BioCardia, Inc. [Nasdaq: BCDA], a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, announced today that the Company has regained full compliance with the Nasdaq Capital Market’s Listing Requirements as required by the Hearing Panel’s (the “Panel”) decision on May 13, 2024.
GlobeNewswire,is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Latest posts by GlobeNewswire (see all)
- Rock N Block Turf N Hardscapes Transforms Las Vegas Outdoor Spaces With Expert Landscaping Services - June 30, 2025
- Oliveda International, Inc. (OLVI) Subsidiary Olive Tree People Canada Inc. Brings Its Waterless Beauty to Canada in July 2025 - June 30, 2025
- Western Uranium & Vanadium Announces Results of AGM and Appoints New Transfer Agent - June 30, 2025
